AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall Street thinks earnings and revenue will decline next year. More than 30% of the float is sold short, creating another reason for caution with ANAB. Today’s Featured Stock Valued at $1.32 billion, AnaptysBio (ANAB) is a biotechnology company. It is involved in the discovery and development of therape ...